Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, Freeman SD, Gilkes AF, Gale RE, Rapoz-D'Silva T, Runglall M, Kleeman M, Dhami P, Thomas I, Johnson S, Canham J, Cavenagh JD, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett AK -, Wilhelm-Benartzi CS, Huntly BJ, Russell NH, Dillon RJ. Othman J, et al. Among authors: wilhelm benartzi cs. Blood. 2024 May 1:blood.2024024310. doi: 10.1182/blood.2024024310. Online ahead of print. Blood. 2024. PMID: 38691678
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, Gilkes A, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Dillon R, Russell NH. Othman J, et al. Among authors: wilhelm benartzi c. Blood. 2024 May 9;143(19):1931-1936. doi: 10.1182/blood.2023023096. Blood. 2024. PMID: 38364112
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. Among authors: wilhelm benartzi c. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes A, Potter N, Overgaard UM, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Dennis M, Russell NH. Othman J, et al. Among authors: wilhelm benartzi c. Blood Adv. 2023 Aug 22;7(16):4539-4549. doi: 10.1182/bloodadvances.2023010276. Blood Adv. 2023. PMID: 37171402 Free PMC article. Clinical Trial.
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.
Wilhelm-Benartzi CS, Miller SE, Bruggraber S, Picton D, Wilson M, Gatley K, Chhabra A, Marcovecchio ML, Hendriks AEJ, Morobé H, Chmura PJ, Bond S, Aschemeier-Fuchs B, Knip M, Tree T, Overbergh L, Pall J, Arnaud O, Haller MJ, Nitsche A, Schulte AM, Mathieu C, Mander A, Dunger D. Wilhelm-Benartzi CS, et al. BMJ Open. 2021 Dec 7;11(12):e053669. doi: 10.1136/bmjopen-2021-053669. BMJ Open. 2021. PMID: 34876434 Free PMC article.
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Willenbrock F, Cox CM, Parkes EE, Wilhelm-Benartzi CS, Abraham AG, Owens R, Sabbagh A, Jones CM, Hughes DLI, Maughan T, Hurt CN, O'Neill EE, Mukherjee S. Willenbrock F, et al. Among authors: wilhelm benartzi cs. Br J Cancer. 2021 Feb;124(3):581-586. doi: 10.1038/s41416-020-01120-z. Epub 2020 Oct 26. Br J Cancer. 2021. PMID: 33100327 Free PMC article. Clinical Trial.
Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia.
Milne P, Wilhelm-Benartzi C, Grunwald MR, Bigley V, Dillon R, Freeman SD, Gallagher K, Publicover A, Pagan S, Marr H, Jones GL, Dickinson AM, Grech A, Burnett AK, Russell NH, Levis M, Knapper S, Collin M. Milne P, et al. Among authors: wilhelm benartzi c. Blood Adv. 2019 Oct 22;3(20):3052-3061. doi: 10.1182/bloodadvances.2019000197. Blood Adv. 2019. PMID: 31648336 Free PMC article.
Prediction of mode of delivery using the first ultrasound-based "intrapartum app".
Usman S, Kahrs BH, Wilhelm-Benartzi C, Hassan WA, Barton H, Salvesen KA, Eggebø TM, Lees C. Usman S, et al. Among authors: wilhelm benartzi c. Am J Obstet Gynecol. 2019 Aug;221(2):163-166. doi: 10.1016/j.ajog.2019.03.019. Epub 2019 Mar 27. Am J Obstet Gynecol. 2019. PMID: 30928568 Free article. No abstract available.
34 results